Skin reaction to adalimumabBEUTHIEN, W; MELLINGHOFF, H.-U; VON KEMPIS, J et al.Arthritis and rheumatism. 2004, Vol 50, Num 5, pp 1690-1692, issn 0004-3591, 3 p.Article

AdalimumabAUBIN, F; BARTHELEMY, H.Annales de dermatologie et de vénéréologie. 2011, Vol 138, Num 12, pp 842-844, issn 0151-9638, 3 p.Article

Differential effect of drug interference in immunogenicity assaysHART, Margreet H; DE VRIEZE, Henk; WOUTERS, Diana et al.Journal of immunological methods. 2011, Vol 372, Num 1-2, pp 196-203, issn 0022-1759, 8 p.Article

Lettre d'information pour le traitement du psoriasis par l'adalimumab (Humira^®) = Information letter on treatment of psoriasis with adalimumab (Humira^®)Annales de dermatologie et de vénéréologie. 2011, Vol 138, Num 12, pp 868-870, issn 0151-9638, 3 p.Article

Frequency and Effectiveness of Dose Increase of Adalimumab, Etanercept, and Infliximab in Daily Clinical PracticeBLOM, M; KIEVIT, W; KUPER, H. H et al.Arthritis care and research. 2010, Vol 62, Num 9, pp 1335-1341, issn 0893-7524, 7 p.Article

Adalimumab : In Plaque PsoriasisCROOM, Katherine F; MCCORMACK, Paul L.American journal of clinical dermatology. 2009, Vol 10, Num 1, pp 43-50, issn 1175-0561, 8 p.Article

Steroid-unresponsive neurosarcoidosis successfully treated with adalimumabMARNANE, Michael; LYNCH, Timothy; SCOTT, Jacqueline et al.Journal of neurology. 2009, Vol 256, Num 1, pp 139-140, issn 0340-5354, 2 p.Article

Successful treatment of psoriatic onycho-pachydermo periostitis (POPP) with adalimumabBONGARTZ, T; HÄRLE, P; FRIEDRICH, S et al.Arthritis and rheumatism. 2005, Vol 52, Num 1, pp 280-282, issn 0004-3591, 3 p.Article

Adalimumab for psoriasis: practical experience in a U.K. tertiary referral centreWARREN, R. B; BROWN, B. C; LAVERY, D et al.British journal of dermatology (1951). 2010, Vol 163, Num 4, pp 859-862, issn 0007-0963, 4 p.Article

Generalized interstitial granuloma annulare - response to adalimumabWERCHAU, Siegfried; ENK, Alexander; HARTMANN, Martin et al.International journal of dermatology. 2010, Vol 49, Num 4, pp 457-460, issn 0011-9059, 4 p.Article

Antibodies to constant domains of therapeutic monoclonal antibodies: Anti-hinge antibodies in immunogenicity testingRISPENS, Theo; DE VRIEZE, Henk; DE GROOT, Els et al.Journal of immunological methods. 2012, Vol 375, Num 1-2, pp 93-99, issn 0022-1759, 7 p.Article

Recalcitrant cutaneous sarcoidosis responding to adalimumab but not to etanerceptFIELD, S; REGAN, A. O; SHEAHAN, K et al.Clinical and experimental dermatology (Print). 2010, Vol 35, Num 7, pp 795-796, issn 0307-6938, 2 p.Article

Adalimumab in the Treatment of Psoriasis: Pooled Efficacy and Safety Results from Three Pivotal StudiesPAPP, Kim; OKUN, Martin; VENDER, Ronald et al.Journal of cutaneous medicine and surgery. 2009, Vol 13, issn 1203-4754, S58-S66, SUP2Article

Successful treatment of granulomatous cheilitis with adalimumabVILLAVERDE, Ricardo Ruiz; VILLAVERDE, Ricardo Ruiz et al.SANCHEZ CANO, Daniel; VILLAVERDE, Ricardo Ruiz; VILLAVERDE, Ricardo Ruiz et al.International journal of dermatology. 2012, Vol 51, Num 1, pp 118-120, issn 0011-9059, 3 p.Article

Safety and Efficacy of Adalimumab for the Treatment of Severe Alopecia Areata: Case Series of Three PatientsBOLDUC, Chantal; BISSONNETTE, Robert.Journal of cutaneous medicine and surgery. 2012, Vol 16, Num 4, pp 257-260, issn 1203-4754, 4 p.Article

Relevance of laboratory investigations in monitoring patients with psoriasis on etanercept or adalimumabVAN LUMIG, P. P. M; DRIESSEN, R. J. B; ROELOFS-THIJSSEN, M. A. M. A et al.British journal of dermatology (1951). 2011, Vol 165, Num 2, pp 375-382, issn 0007-0963, 8 p.Article

Alopecia Areata Following AdalimumabKIRSHEN, Carly; KANIGSBERG, Nordau.Journal of cutaneous medicine and surgery. 2009, Vol 13, Num 1, pp 48-50, issn 1203-4754, 3 p.Article

Hyperpigmentation of the Face Following Adalimumab TreatmentBLOMBERG, Maria; ZACHARIAE, Claus; GRØNHØJ, Frederik et al.Acta dermato-venereologica. 2009, Vol 89, Num 5, pp 546-548, issn 0001-5555, 3 p.Article

Adalimumab Treatment for SAPHO SyndromeARIAS-SANTIAGO, Salvador; SANCHEZ-CANO, Daniel; CALLEJAS-RUBIO, José Luis et al.Acta dermato-venereologica. 2010, Vol 90, Num 3, pp 301-302, issn 0001-5555, 2 p.Article

Does adalimumab cause bullous pemphigoid?TOOSI, S; BYSTRYN, J.-C.Clinical and experimental dermatology (Print). 2010, Vol 35, Num 7, issn 0307-6938, p. 795Article

Recurrent Hyperglycemia During Adalimumab Treatment in a Patient With PsoriasisWU, Jia-Jen; TSAI, Tsen-Fang.Archives of dermatology (1960). 2008, Vol 144, Num 10, pp 1403-1404, issn 0003-987X, 2 p.Article

Type I Reaction of Hansen's Disease With Exposure to Adalimumab: A Case ReportOBERSTEIN, Elana M; KROMO, Olga; TOZMAN, Elaine C et al.Arthritis care and research. 2008, Vol 59, Num 7, pp 1040-1043, issn 0893-7524, 4 p.Article

Pyoderma gangrenosum possibly triggered by adalimumabKIKUCHI, Nobuyuki; HIRAIWA, Tomoko; OHASHI, Takenobu et al.EJD. European journal of dermatology. 2012, Vol 22, Num 6, pp 804-805, issn 1167-1122, 2 p.Article

Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-label Phase IIIB trialSTROBER, B. E; SOBELL, J. M; DUFFIN, K. C et al.British journal of dermatology (1951). 2012, Vol 167, Num 6, pp 1374-1381, issn 0007-0963, 8 p.Article

Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapyPAPP, K; CROWLEY, J; ORTONNE, J.-P et al.British journal of dermatology (1951). 2011, Vol 164, Num 2, pp 434-441, issn 0007-0963, 8 p.Article